Don’t stress about CRF: assessing the translational failures of CRF1antagonists

Psychopharmacology

Volumn 234, Issue 9-10, 2017, Pages 1467-1481

  Spierling, Samantha R ^a   Zorrilla, Eric P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Alcohol dependence; Alcohol use disorder; Alcoholism; Antidepressant or anxiolytic; Binge drinking; Binge eating; Clinical trial; Corticotropin releasing factor; Corticotropin releasing hormone; CRF; CRF1 receptor antagonist; CRH; CRH1 receptor antagonist; Drug addiction; Food addiction; Generalized anxiety disorder; Irritable bowel syndrome; Major depression; Panic disorder; Post traumatic stress disorder; Translation; Treatment

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CP 316311; EMICERFONT; ONO 2333MS; PEXACERFONT; PF 00572778; UNCLASSIFIED DRUG; VERUCERFONT; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ALCOHOLISM; ALLOSTERISM; ANTIDEPRESSANT ACTIVITY; BOLD SIGNAL; COCAINE DEPENDENCE; CRHBP GENE; CRHR1 GENE; CRHR2 GENE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSPHORIA; ENZYME ACTIVATION; FOOD CRAVING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEROIN DEPENDENCE; HUMAN; IRRITABLE COLON; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL PHOBIA; SUICIDAL IDEATION; TRANQUILIZING ACTIVITY; ADDICTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSION; DRUG DEPENDENCE; MENTAL STRESS; METABOLISM; PROCEDURES; TRANSLATIONAL RESEARCH;

ANIMALS; BEHAVIOR, ADDICTIVE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; HUMANS; PYRIMIDINES; PYRROLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL; SUBSTANCE-RELATED DISORDERS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85014533716     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-017-4556-2     Document Type: Review

References (175)

1. Abruzzo PM, Ghezzo A, Bolotta A, Ferreri C, Minguzzi R, Vignini A, Visconti P, Marini M (2015) Perspective biological markers for autism spectrum disorders: advantages of the use of receiver operating characteristic curves in evaluating marker sensitivity and specificity. Dis Markers 2015:329607
2. Albrechet-Souza L, Hwa LS, Han X, Zhang EY, DeBold JF, Miczek KA (2015) Corticotropin releasing factor binding protein and CRF2 receptors in the ventral tegmental area: modulation of ethanol binge drinking in C57BL/6J mice. Alcohol Clin Exp Res 39(9):1609–1618
3. Anthony TE, Dee N, Bernard A, Lerchner W, Heintz N, Anderson DJ (2014) Control of stress-induced persistent anxiety by an extra-amygdala septohypothalamic circuit. Cell 156(3):522–536
4. Bai Q, Shi D, Zhang Y, Liu H, Yao X (2014) Exploration of the antagonist CP-376395 escape pathway for the corticotropin-releasing factor receptor 1 by random acceleration molecular dynamics simulations. Mol BioSyst 10:1958–1967
5. Bailey JE, Papadopoulos A, Diaper A, Phillips S, Schmidt ME, van der Ark P, Dourish CT, Dawson GR, Nutt DJ (2011) Preliminary evidence of anxiolytic effects of the CRF receptor antagonist R317573 in the 7.5% CO proof-of-concept experimental model of human anxiety. J Psychopharmacol 25(9):1199–1206
6. Bakshi VP, Newman SM, Smith-Roe S, Jochman KA, Kalin NH (2007) Stimulation of lateral septum CRF2 receptors promotes anorexia and stress-like behaviors: functional homology to CRF1 receptors in basolateral amygdala. J Neurosci 27(39):10568–10577
7. Bangasser DA, Valentino RJ (2012) Sex differences in molecular and cellular substrates of stress. Cell Mol Neurobiol 32:709–723
8. Bangasser DA, Curtis A, Reyes BA, Bethea TT, Parastatidis I, Ischiropoulos H, Van Bockstaele EJ, Valentino RJ (2010) Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. Mol Psychiatry 15(877):896–904
9. Barr CS, Dvoskin RL, Yuan Q, Lipsky RH, Gupte M, Hu X, Zhou Z, Schwandt ML, Lindell SG, McKee M, Becker ML, Kling MA, Gold PW, Higley D, Heilig M, Suomi SJ, Goldman D (2008) CRH haplotype as a factor influencing cerebrospinal fluid levels of corticotropin-releasing hormone, hypothalamic-pituitary-adrenal axis activity, temperament, and alcohol consumption in rhesus macaques. Arch Gen Psychiatry 65(8):934–944
10. Belzung C (2014) Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects? Neuropsychopharmacology 39:1041–1051
11. Berrettini W (2016) Opioid neuroscience for addiction medicine: from animal models to FDA approval for alcohol addiction. Prog Brain Res 223:253–267
12. Besheer J, Frisbee S, Randall PA, Jaramillo AA, Masciello M (2016) Gabapentin potentiates sensitivity to the interoceptive effects of alcohol and increases alcohol self-administration in rats. Neuropharmacology 101:216–224
13. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T (2008) A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165:617–620
14. Bonfiglio JJ, Inda C, Senin S, Maccarrone G, Refojo D, Giacomini D, Turck CW, Holsboer F, Arzt E, Silberstein S (2013) B-Raf and CRHR1 internalization mediate biphasic ERK1/2 activation by CRH in hippocampal HT22 cells. Mol Endocrinol 27:491–510
15. Bonnet U, Specka M, Leweke FM, Nyhuis P, Banger M (2007) Gabapentin’s acute effect on mood profile: a controlled study on patients with alcohol withdrawal. Prog Neuro-Psychopharmacol Biol Psychiatry 31:434–438
16. Breen ME, Seifuddin F, Zandi PP, Potash JB, Willour VL (2015) Investigating the role of early childhood abuse and HPA axis genes in suicide attempters with bipolar disorder. Psychiatr Genet 25:106–111
17. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA (2008) A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 32:1429–1438
18. Bruijnzeel AW, Markou A (2003) Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse 50:20–28
19. Brunson KL, Schultz L, Baram TZ (1998) The in vivo proconvulsant effects of corticotropin releasing hormone in the developing rat are independent of ionotropic glutamate receptor activation. Dev Brain Res 111(1):119–128
20. Buttenschøn HN, Krogh J, Nielsen MN, Kaerlev L, Nordentoft M, Mors O (2016) Association analyses of depression and genes in the hypothalamus-pituitary-adrenal axis. Acta Neuropsychiatr 6:1–6
21. Chang HS, Won E, Lee HY, Ham BJ, Lee MS (2015) Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants. Behav Brain Res 292:116–124
22. Chen B, Tao G, Ma B, Zheng G, Ke B, Zhang X, Zhang L, Wang Y, Hu L, Yang C, Qiu J, Nie S (2014) The CRHR1 gene contributes to genetic susceptibility of aggressive behavior towards others in chinese southwest han population. J Mol Neurosci 52(4):481–486
23. Ching-López A, Cervilla J, Rivera M, Molina E, McKenney K, Ruiz-Perez I, Rodríguez-Barranco M, Gutiérrez B (2015) Epidemiological support for genetic variability at hypothalamic-pituitary-adrenal axis and serotonergic system as risk factors for major depression. Neuropsychiatr Dis Treat 11:2743–2754
24. Cippitelli A, Damadzic R, Singley E, Thorsell A, Ciccocioppo R, Eskay RL, Heilig M (2012) Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats. Pharmacol Biochem Behav 100:522–529
25. Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH (2014) Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14(3):303–308
26. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG (2010) Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27:417–425
27. Cottone P, Sabino V, Roberto M, Bajo M, Pockros L, Frihauf JB, Fekete EM, Steardo L, Rice KC, Grigoriadis DE, Conti B, Koob GF, Zorrilla EP (2009) CRF system recruitment mediates dark side of compulsive eating. Proc Natl Acad Sci 106(47):20016–20020
28. Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH (2013) An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 38(10):2003–2010. doi:10.1038/npp.2013.99 [Erratum: Neuropsychopharmacology (2014) 39(4):1039]
29. Crist RC, Doyle GA, Nelson EC, Degenhardt L, Martin NG, Montgomery GW, Saxon AJ, Ling W, Berrettini WH (2016) A polymorphism in the OPRM1 3′-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J. doi:10.1038/tpj.2016.89
30. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003a) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168:347–358
31. Cryan JF, Gasparini F, van Heeke G, Markou A (2003b) Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov Today 8:1025–1034
32. Dunn HA, Chahal HS, Caetano FA, Holmes KD, Yuan GY, Parikh R, Heit B, Ferguson SS (2016) PSD-95 regulates CRFR1 localization, trafficking and β-arrestin2 recruitment. Cell Signal 28:531–540
33. Demers CH, Conley ED, Bogdan R, Hariri AR (2016) Interactions between anandamide and corticotropin-releasing factor signaling modulate human amygdala function and risk for anxiety disorders: an imaging genetics strategy for modeling molecular interactions. Biol Psychiatry 80(5):356–362
34. Epstein DH, Kennedy AP, Furnari M, Heilig M, Shaham Y, Phillips KA, Preston KL (2016) Effect of the CRF1-receptor antagonist pexacerfont on stress-induced eating and food craving. Psychopharmacology 233(23–24):3921–3932
35. Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE (2012) Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J Pharmacol Exp Ther 341:518–531
36. Ghitza UE, Gray SM, Epstein DH, Rice KC, Shaham Y (2006) The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors. Neuropsychopharmacology 31:2188–2196
37. Gilpin NW, Richardson HN, Koob GF (2008) Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. Alcohol Clin Exp Res 32:1535–1542
38. Gingell JJ, Simms J, Barwell J, Poyner DR, Watkins HA, Pioszak AA, Sexton PM, Hay DL (2016) An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. Cell Discov 2:16012
39. Gomez F, Manalo S, Dallman MF (2004) Androgen-sensitive changes in regulation of restraint-induced adrenocorticotropin secretion between early and late puberty in male rats. Endocrinology 145:59–70
40. Goodman SN (1999) Toward evidence-based medical statistics. 2: the bayes factor. Ann Intern Med 130(12):1005
41. Griebel G, Holmes A (2013) 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 12:667–687
42. Grillon C, Hale E, Lieberman L, Davis A, Pine DS, Ernst M (2015) The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. Neuropsychopharmacology 40:1064–1071
43. Grimm S, Gärtner M, Fuge P, Fan Y, Weigand A, Feeser M, Aust S, Heekeren HR, Jacobs A, Heuser I, Bajbouj M (2015) Variation in the corticotropin-releasing hormone receptor 1 (CRHR1) gene modulates age effects on working memory. J Psychiatr Res 61:57–63
44. Haass-Koffler CL, Henry AT, Melkus G, Simms JA, Naemmuddin M, Nielsen CK, Lasek AW, Magill M, Schwandt ML, Momenan R, Hodgkinson CA, Bartlett SE, Swift RM, Bonci A, Leggio L (2016) Defining the role of corticotropin releasing factor binding protein in alcohol consumption. Transl Psychiatry 6(11):e953
45. Haller J, Aliczki M, Gyimesine Pelczer K (2013) Classical and novel approaches to the preclinical testing of anxiolytics: a critical evaluation. Neurosci Biobehav Rev 37:2318–2330
46. Harrison AA, Markou A (2001) Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors. J Pharmacol Exp Ther 297:316–325
47. Harrison AA, Liem YT, Markou A (2001) Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25:55–71
48. Hausch F (2013) Structures of class B G protein-coupled receptors: prospects for drug discovery. Angew Chem Int Ed Engl 52:12783–12785
49. Heilig M, Leggio L (2016) What the alcohol doctor ordered from the neuroscientist: theragnostic biomarkers for personalized treatments. Prog Brain Res 224:401–418
50. Heilig M, Goldman D, Berrettini W, O'Brien CP (2011) Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12(11):670–684
51. Heilig M, Sommer WH, Spanagel R (2016) The need for treatment responsive translational biomarkers in alcoholism research. Curr Top Behav Neurosci 28:151–171
52. Heinzerling KG, Demirdjian L, Wu Y, Shoptaw S (2016) Single nucleotide polymorphism near CREB1, rs7591784, is associated with pretreatment methamphetamine use frequency and outcome of outpatient treatment for methamphetamine use disorder. J Psychiatr Res 74:22–29
53. Held K, Kunzel H, Ising M, Schmid DA, Zobel A, Murck H, Holsboer F, Steiger A (2004) Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res 38:129–136
54. Henry B, Vale W, Markou A (2006) The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 26:9142–9152
55. Heyser CJ, Schulteis G, Durbin P, Koob GF (1998) Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 18:125–133
56. Heyser CJ, Moc K, Koob GF (2003) Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology 28:1463–1471
57. Hollenstein K, Kean J, Bortolato A, Cheng RK, Doré AS, Jazayeri A, Cooke RM, Weir M, Marshall FH (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499:438–443
58. Holsboer F, Ising M (2010) Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 61:81–109 C1-C11
59. Huang MM, Overstreet DH, Knapp DJ, Angel R, Wills TA, Navarro M, Rivier J, Vale W, Breese GR (2010) Corticotropin-releasing factor (CRF) sensitization of ethanol withdrawal-induced anxiety-like behavior is brain site specific and mediated by CRF-1 receptors: relation to stress-induced sensitization. J Pharmacol Exp The 332:298–307
60. Hubbard CS, Labus JS, Bueller J, Stains J, Suyenobu B, Dukes GE, Kelleher DL, Tillisch K, Naliboff BD, Mayer EA (2011) Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. J Neurosci 31(35):12491–12500
61. Hyman SE (2012) Revolution stalled. Sci Transl Med 4(155):155cm11
62. Ji D, Gilpin NW, Richardson HN, Rivier CL, Koob GF (2008) Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol 19:1–12
63. Jones JD, Comer SD (2015) A review of pharmacogenetic studies of substance-related disorders. Drug Alcohol Depend 152:1–14
64. Kalin NH, Fox AS, Kovner R, Riedel MK, Fekete EM, Roseboom PH, do PM T, Grabow BP, Olsen ME, Brodsky EK, McFarlin DR, Alexander AL, Emborg ME, Block WF, Fudge JL, Oler JA (2016) Overexpressing corticotropin-releasing factor in the primate amygdala increases anxious temperament and alters its neural circuit. Biol Psychiatry 80:345–355
65. Keating GM (2013) Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs 27:761–772
66. Kehne JH, Coverdale S, McCloskey TC, Hoffman DC, Cassella JV (2000) Effects of the CRF1 receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 39:1357–1367
67. Ketchesin KD, Stinnett GS, Seasholtz AF (2016) Binge drinking decreases corticotropin-releasing factor-binding protein expression in the medial prefrontal cortex of mice. Alcohol Clin Exp Res 40(8):1641–1650
68. Khalilova Z, Zainullina A, Khusnutdinova E (2014) Association analysis of CRHR1 gene, FKBP5 gene and YWHAE gene with suicidal behavior inindividuals from Russia. Eur Neuropsychopharmacol 24:S577
69. Komuro H, Sato N, Sasaki A, Suzuki N, Kano M, Tanaka Y, Yamaguchi-Kabata Y, Kanazawa M, Warita H, Aoki M, Fukudo S (2016) Corticotropin-releasing hormone receptor 2 gene variants in irritable bowel syndrome. PLoS One 11(1):e0147817
70. Koob GF, Zorrilla EP (2012) Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacol Rev 37:308–309
71. Kostich WA, Chen A, Sperle K, Largent BL (1998) Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol 12(8):1077–1085
72. Krishnan B, Centeno M, Pollandt S, Fu Y, Genzer K, Liu J, Gallagher JP, Shinnick-Gallagher P (2010) Dopamine receptor mechanisms mediate corticotropin-releasing factor-induced long-term potentiation in the rat amygdala following cocaine withdrawal. Eur J Neurosci 31:1027–1042
73. Künzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, Ising M, Holsboer F (2003) Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37(6):525–533
74. Künzel HE, Ising M, Zobel AW, Nickel T, Ackl N, Sonntag A, Holsboer F, Uhr M (2005) Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression. J Psychiatr Res 39(2):173–177
75. Kwako LE, Spagnolo PA, Schwandt ML, Thorsell A, George DT, Momenan R, Rio DE, Huestis M, Anizan S, Concheiro M, Sinha R, Heilig M (2015) The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology 40:1053–1063
76. Lee Y, Fitz S, Johnson PL, Shekhar A (2008) Repeated stimulation of CRF receptors in the BNST of rats selectively induces social but not panic-like anxiety. Neuropsychopharmacology 33:2586–2594
77. Levran O, Randesi M, Li Y, Rotrosen J, Ott J, Adelson M, Kreek MJ (2014) Drug addiction and stress-response genetic variability: association study in African Americans. Ann Hum Genet 78:290–228
78. Licinio J, O'Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R, Lake S, Tantisira KG, Weiss ST, Wong ML (2004) Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 9:1075–1082
79. Lin D, Koob GF, Markou A (1999) Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat: interactions between the two drugs. Psychopharmacology 145:283–294
80. Liu Z, Zhu F, Wang G, Xiao Z, Wang H, Tang J, Wang X, Qiu D, Liu W, Cao Z, Li W (2006) Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett 404:358–362
81. Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, Wang H, Liu H, Wang X, Wu Y, Cao Z, Li W (2007) Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 414:155–158
82. Lodge NJ, Li YW, Chin FT, Dischino DD, Zoghbi SS, Deskus JA, Mattson RJ, Imaizumi M, Pieschl R, Molski TF, Fujita M, Dulac H, Zaczek R, Bronson JJ, Macor JE, Innis RB, Pike VW (2014) Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors. Nucl Med Biol 41:524–535
83. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, de Souza EB, Oltersdorf T (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A 92:836–840
84. Lowery EG, Sparrow AM, Breese GR, Knapp DJ, Thiele TE (2008) The CRF-1 receptor antagonist, CP-154,526, attenuates stress-induced increases in ethanol consumption by BALB/cJ mice. Alcohol Clin Exp Res 32:240–248
85. Lowery EG, Spanos M, Navarro M, Lyons AM, Hodge CW, Thiele TE (2010) CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL/6J mice independent of the HPA axis. Neuropsychopharmacology 35:1241–1252
86. Macey DJ, Koob GF, Markou A (2000) CRF and urocortin decreased brain stimulation reward in the rat: reversal by a CRF receptor antagonist. Brain Res 866:82–91
87. Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN, Drysdale L, Poulter MO, Roth BL, Pin J-P, Anisman H, Ferguson SSG (2010) CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci 13(5):622–629
88. Mahon PB, Zandi PP, Potash JB, Nestadt G, Wand GS (2013) Genetic association of FKBP5 and CRHR1 with cortisol response to acute psychosocial stress in healthy adults. Psychopharmacology 227:231–241
89. Malcolm R, Myrick LH, Veatch LM, Boyle E, Randall PK (2007) Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. J Clin Sleep Med 3:24–32
90. Mansbach RS, Brooks EN, Chen YL (1997) Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 323:21–26
91. Mantsch JR, Baker DA, Funk D, Lê AD, Shaham Y (2016) Stress-induced reinstatement of drug seeking: 20 years of progress. Neuropsychopharmacology 41:335–356
92. Markou A (2007) Metabotropic glutamate receptor antagonists: novel therapeutics for nicotine dependence and depression? Biol Psychiatry 61:17–22
93. Markou A, Cryan JF (2012) Stress, anxiety and depression: toward new treatment strategies. Neuropharmacology 62:1–2
94. Markou A, Kosten TR, Koob GF (1998) Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18:135–174
95. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A (2014) Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 174:70–77
96. Miao Y, McCammon JA (2016) G-protein coupled receptors: advances in simulation and drug discovery. Curr Opin Struct Biol 41:83–89
97. Milan-Lobo L, Gsandtner I, Gaubitzer E, Rünzler D, Buchmayer F, Köhler G, Bonci A, Freissmuth M, Sitte HH (2009) Subtype-specific differences in corticotropin-releasing factor receptor complexes detected by fluorescence spectroscopy. Mol Pharmacol 76(6):1196–1210
98. Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL (2009) A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 33:1582–1588
99. Narla C, Scidmore T, Jeong J, Everest M, Chidiac P, Poulter MO (2016) A switch in G protein coupling for type 1 corticotropin-releasing factor receptors promotes excitability in epileptic brains. Sci Signal 9:ra60
100. Nelson EC, Agrawal A, Pergadia ML, Wang JC, Whitfield JB, Saccone FS, Kern J, Grant JD, Schrage AJ, Rice JP, Montgomery GW, Heath AC, Goate AM, Martin NG, Madden PA (2010) H2 haplotype at chromosome 17q21.31 protects against childhood sexual abuse-associated risk for alcohol consumption and dependence. Addict Biol 1:1–11
101. Oedegaard KJ, Alda M, Anand A, Andreassen OA, Balaraman Y, Berrettini WH, Bhattacharjee A, Brennand KJ, Burdick KE, Calabrese JR, Calkin CV, Claasen A, Coryell WH, Craig D, DeModena A, Frye M, Gage FH, Gao K, Garnham J, Gershon E, Jakobsen P, Leckband SG, McCarthy MJ, McInnis MG, Maihofer AX, Mertens J, Morken G, Nievergelt CM, Nurnberger J, Pham S, Schoeyen H, Shekhtman T, Shilling PD, Szelinger S, Tarwater B, Yao J, Zandi PP, Kelsoe JR (2016) The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample. BMC Psychiatry 16:129
102. Orand A, Naliboff B, Gadd M, Shih W, Ju T, Presson AP, Mayer EA, Chang L (2016) Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response. Psychoneuroendocrinology 73:133–141
103. Pagliaccio D, Luby JL, Bogdan R, Agrawal A, Gaffrey MS, Belden AC, Botteron KN, Harms MP, Barch DM (2015) HPA axis genetic variation, pubertal status, and sex interact to predict amygdala and hippocampus responses to negative emotional faces in school-age children. NeuroImage 109:1–11
104. Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F (2015) Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med 12:e1001924
105. Paterson NE, Markou A (2007) Animal models and treatments for addiction and depression co-morbidity. Neurotox Res 11:1–32
106. Paterson NE, Balfour DJ, Markou A (2007) Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci 25:3099–3108
107. Paterson NE, Balfour DJ, Markou A (2008a) Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats. Nicotine Tob Res 10:995–1008
108. Paterson NE, Semenova S, Markou A (2008b) The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat. Psychopharmacology 198:351–362
109. Plosker GL (2015) Acamprosate: a review of its use in alcohol dependence. Drugs 75:1255–1268
110. Quadros IM, Macedo GC, Domingues LP, Favoretto CA (2016) An update on CRF mechanisms underlying alcohol use disorders and dependence. Front Endocrinol (Lausanne) 7:134
111. Rainnie DG, Bergeron R, Sajdyk TJ, Patil M, Gehlert DR, Shekhar A (2004) Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. J Neurosci 24:3471–3479
112. Rajbhandari AK, Baldo BA, Bakshi VP (2015) Predator stress- induced CRF release causes enduring sensitization of basolateral amygdala norepinephrine systems that promote PTSD-like startle abnormalities. J Neurosci 35(42):14270–14285
113. Rassnick S, Pulvirenti L, Koob GF (1992) Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacology 109:92–98
114. Ray B, Gaskins DL, Sajdyk TJ, Spence JP, Fitz SD, Shekhar A, Lahiri DK (2011) Restraint stress and repeated corticotrophin-releasing factor receptor activation in the amygdala both increase amyloid-β precursor protein and amyloid-β peptide but have divergent effects on brain-derived neurotrophic factor and pre-synaptic proteins in the prefrontal cortex of rats. Neuroscience 184:139–150
115. Roberto M, Gilpin NW, O’Dell LE, Cruz MT, Morse AC, Siggins GR, Koob GF (2008) Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci 28:5762–5771
116. Rosenthal R, Rubin DB (1994) The counternull value of an effect size: a new statistic. Psychol Sci 5:329–334
117. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (2010) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 12:CD001867
118. Sabino V, Cottone P, Koob GF, Steardo L, Lee MJ, Rice KC, Zorrilla EP (2006) Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. Psychopharmacology 189:175–186
119. Sabino V, Kwak J, Rice KC, Cottone P (2013) Pharmacological characterization of the 20% alcohol intermittent access model in alcohol-preferring rats: a model of binge-like drinking. Alcohol Clin Exp Res 37:635–643
120. Sajdyk TJ, Schober DA, Gehlert DR, Shekhar A (1999) Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res 100:207–215
121. Sanchez MM, Young LJ, Plotsky PM, Insel TR (1999) Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 408:365–377
122. Sanders J, Nemeroff C (2016) The CRF system as a therapeutic target for neuropsychiatric disorders. Trends Pharmacol Sci 37:1045–1054
123. Sasaki A, Sato N, Suzuki N, Kano M, Tanaka Y, Kanazawa M, Aoki M, Fukudo S (2016) Associations between single-nucleotide polymorphisms in corticotropin-releasing hormone-related genes and irritable bowel syndrome. PLoS One 11:e0149322
124. Schmidt ME, Andrews RD, van der Ark P, Brown T, Mannaert E, Steckler T, de Hoon J, Van Laere K (2010) Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology 208:109–119
125. Schwandt ML, Cortes CR, Kwako LE, George DT, Momenan R, Sinha R, Grigoriadis DE, Pich EM, Leggio L, Heilig M (2016) The CRF1 antagonist verucerfont in anxious alcohol-dependent women: translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacology 41:2818–2829
126. Shaham Y, de Wit H (2016) Lost in translation: CRF1 ereceptor antagonists and addiction treatment. Neuropsychopharmacology 41:2795–2797
127. Simms JA, Haass-Koffler CL, Bito-Onon J, Li R, Bartlett SE (2012) Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacology 37:906–918
128. Simms JA, Nielsen CK, Li R, Bartlett SE (2014) Intermittent access ethanol consumption dysregulates CRF function in the hypothalamus and is attenuated by the CRF-R1 antagonist, CP-376395. Addict Biol 19:606–611
129. Sinha R, Fox HC, Hong KI, Hansen J, Tuit K, Kreek MJ (2011) Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch Gen Psychiatry 68:942–952
130. Slater PG, Cerda CA, Pereira LA, Andrés ME, Gysling K (2016a) CRF binding protein facilitates the presence of CRF type 2α receptor on the cell surface. Proc Natl Acad Sci U S A 113(15):4075–4080
131. Slater PG, Noches V, Gysling K (2016b) Corticotropin-releasing factor type-2 receptor and corticotropin-releasing factor-binding protein coexist in rat ventral tegmental area nerve terminals originated in the lateral hypothalamic area. Eur J Neurosci 43(2):220–229
132. Smoller JW (2016) The genetics of stress-related disorders: PTSD, depression, and anxiety disorders. Neuropsychopharmacology 41:297–319
133. Sparta DR, Sparrow AM, Lowery EG, Fee JR, Knapp DJ, Thiele TE (2008) Blockade of the corticotropin releasing factor type 1 receptor attenuates elevated ethanol drinking associated with drinking in the dark procedures. Alcohol Clin Exp Res 32:259–265
134. Sparta DR, Ferraro FM III, Fee JR, Knapp DJ, Breese GR, Thiele TE (2009) The alcohol deprivation effect in C57BL/6J mice is observed using operant self-administration procedures and is modulated by CRF-1 receptor signaling. Alcohol Clin Exp Res 33:31–42
135. Stehouwer JS, Bourke CH, Owens MJ, Voll RJ, Kilts CD, Goodman MM (2015a) Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihyd ropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) receptors. Bioorg Med Chem Lett 25:5111–5114
136. Stehouwer JS, Birnbaum MS, Voll RJ, Owens MJ, Plott SJ, Bourke CH, Wassef MA, Kilts CD, Goodman MM (2015b) Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin -7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor. Bioorg Med Chem 23:4286–4302
137. Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J, Morgan MY (2015) Nalmefene for reducing alcohol consumption in people with alcohol dependence: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics 33:833–847
138. Stewart AM, Nguyen M, Poudel MK, Warnick JE, Echevarria DJ, Beaton EA, Song C, Kalueff AV (2015) The failure of anxiolytic therapies in early clinical trials: what needs to be done. Expert Opin Investig Drugs 24:543–556
139. Stoker AK, Olivier B, Markou A (2012) Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal. Psychopharmacology 221:317–327
140. Suen JY, Cotterell A, Lohman RJ, Lim J, Han A, Yau MK, Liu L, Cooper MA, Vesey DA, Fairlie DP (2014) Pathway-selective antagonism of proteinase activated receptor 2. Br J Pharmacol 171:4112–4124
141. Sweetser S, Camilleri M, Linker Nord SJ, Burton DD, Castenada L, Croop R, Tong G, Dockens R, Zinsmeister AR (2009) Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol 296:G1299–G1306
142. Sztainberg Y, Kuperman Y, Justice N, Chen A (2011) An anxiolytic role for CRF receptor type 1 in the globus pallidus. J Neurosci 31(48):17416–17424
143. Takamatsu Y, Yamamoto H, Ogai Y, Hagino Y, Markou A, Ikeda K (2006) Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice. Ann N Y Acad Sci 1074:295–302
144. Takamatsu Y, Yamamoto H, Hagino Y, Markou A, Ikeda K (2011) The selective serotonin reuptake inhibitor paroxetine, but not fluvoxamine, decreases methamphetamine conditioned place preference in mice. Curr Neuropharmacol 9:68–72
145. Tan EC, Chua TE, Lee TM, Tan HS, Ting JL, Chen HY (2015) Case-control study of glucocorticoid receptor and corticotrophin-releasing hormone receptor gene variants and risk of perinatal depression. BMC Pregnancy Childbirth 15:283
146. Tanaka Y, Kanazawa M, Kano M, Morishita J, Hamaguchi T, Van Oudenhove L, Ly HG, Dupont P, Tack J, Yamaguchi T, Yanai K, Tashiro M, Fukudo S (2016) Differential activation in amygdala and plasma noradrenaline during colorectal distention by administration of corticotropin-releasing hormone between healthy individuals and patients with irritable bowel syndrome. PLoS One 11:e0157347
147. Tellew JE, Lanier M, Moorjani M, Lin E, Luo Z, Slee DH, Zhang X, Hoare SR, Grigoriadis DE, St Denis Y, Di Fabio R, Di Modugno E, Saunders J, Williams JP (2010) Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Bioorg Med Chem Lett 20:7259–7264
148. Treutlein J, Kissling C, Frank J, Wiemann S, Dong L, Depner M, Saam C, Lascorz J, Soyka M, Preuss UW, Rujescu D, Skowronek MH, Rietschel M, Spanagel R, Heinz A, Laucht M, Mann K, Schumann G (2006) Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol Psychiatry 11(6):594–602
149. Turcu AF, Spencer-Segal JL, Farber RH, Luo R, Grigoriadis DE, Ramm CA, Madrigal D, Muth T, O'Brien CF, Auchus RJ (2016) Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 101:1174–1180
150. Ungless MA, Singh V, Crowder TL, Yaka R, Ron D, Bonci A (2003) Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons. Neuron 39(3):401–407
151. Valentino RJ, Bangasser D, Van Bockstaele EJ (2013a) Sex-biased stress signaling: the corticotropin-releasing factor receptor as a model. Mol Pharmacol 83:737–745
152. Valentino RJ, Van Bockstaele E, Bangasser D (2013b) Sex-specific cell signaling: the corticotropin-releasing factor receptor model. Trends Pharmacol Sci 34:437–444
153. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428:191–212
154. Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield T Jr, Logrip ML, Rivier CL, Repunte-Canonigo V, Zorrilla EP, Sanna PP, Heilig M, Koob GF (2012) Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. J Neurosci 32:7563–7571
155. Ventura-Juncá R, Symon A, López P, Fiedler JL, Rojas G, Heskia C, Lara P, Marín F, Guajardo V, Araya AV, Sasso J, Herrera L (2014) Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study. BMC Psychiatry 14:220
156. Walker BM, Koob GF (2008) Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence. Neuropsychopharmacology 33:643–652
157. Walker D, Yang Y, Ratti E, Corsi M, Trist D, Davis M (2009) Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses. Neuropsychopharmacology 34:1533–1542
158. Walther C, Caetano FA, Dunn HA, Ferguson SS (2015) PDZK1/NHERF3 differentially regulates corticotropin-releasing factor receptor 1 and serotonin 2A receptor signaling and endocytosis. Cell Signal 27:519–531
159. Wang B, You ZB, Rice KC, Wise RA (2007) Stress-induced relapse to cocaine seeking: roles for the CRF(2) receptor and CRF-binding protein in the ventral tegmental area of the rat. Psychopharmacology 193(2):283–294
160. Watson WP, Robinson E, Little HJ (1997) The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology 36:1369–1375
161. Weber H, Richter J, Straube B, Lueken U, Domschke K, Schartner C, Klauke B, Baumann C, Pané-Farré C, Jacob CP, Scholz CJ, Zwanzger P, Lang T, Fehm L, Jansen A, Konrad C, Fydrich T, Wittmann A, Pfleiderer B, Ströhle A, Gerlach AL, Alpers GW, Arolt V, Pauli P, Wittchen HU, Kent L, Hamm A, Kircher T, Deckert J, Reif A (2016) Allelic variation in CRHR1 predisposes to panic disorder: evidence for biased fear processing. Mol Psychiatry 21:813–822
162. Weston C, Winfield I, Harris M, Hodgson R, Shah A, Dowell SJ, Mobarec JC, Woodlock DA, Reynolds CA, Poyner DR, Watkins HA, Ladds G (2016) Receptor activity-modifying protein-directed G protein signaling specificity for the calcitonin gene-related peptide family of receptors. J Biol Chem 291:21925–21944 [erratum: 291(49):25763]
163. Westphal NJ, Seasholtz AF (2006) CRH-BP: the regulation and function of a phylogenetically conserved binding protein. Front Biosci 11:1878–1891
164. Wootten D, Lindmark H, Kadmiel M, Willcockson H, Caron KM, Barwell J, Drmota T, Poyner DR (2013) Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function. Br J Pharmacol 168:822–834
165. Xu J, Wang Z, Liu P, Li D, Lin J (2015) An insight into antagonist binding and induced conformational dynamics of class B GPCR corticotropin-releasing factor receptor 1. Mol BioSyst 11:2042–2050
166. Yang X, Wang S, Rice KC, Munro CA, Wand GS (2008) Restraint stress and ethanol consumption in two mouse strains. Alcohol Clin Exp Res 32:840–852
167. Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE (2016) 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4′-pyridylcarboxamido)morphin an (NAP) modulating the mu opioid receptor in a biased fashion. ACS Chem Neurosci 7:297–304
168. Zhao J, Qi XR, Gao SF, Lu J, van Wamelen DJ, Kamphuis W, Bao AM, Swaab DF (2015) Different stress-related gene expression in depression and suicide. J Psychiatr Res 68:176–185
169. Zheng Y, Qin L, Zacarías NV, de Vries H, Han GW, Gustavsson M, Dabros M, Zhao C, Cherney RJ, Carter P, Stamos D, Abagyan R, Cherezov V, Stevens RC, IJzerman AP, Heitman LH, Tebben A, Kufareva I, Handel TM (2016) Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature. doi:10.1038/nature20605
170. Zmijewski MA, Slominski AT (2010) Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim Pol 57:1–13
171. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171–181
172. Zorrilla EP, Koob GF (2004) The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Invest Drugs 13:799–828
173. Zorrilla EP, Koob GF (2010) Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 15:371–383
174. Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A (2002) Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952:188–199
175. Zorrilla EP, Heilig M, de Wit H, Shaham Y (2013) Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend 128:175–186